6th World Congress of the World Society for Pediatric Infectious Diseases (WSPID)

References

• Orenstein W, Landry S, Mitchell V. Vaccines for developing countries. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 1036).
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Rotavirus surveillance – worldwide, 2001–2008. MMWR Morb. Mortal. Wkly Rep.57(46), 1255–1272 (2008).
   PubMedGoogle Scholar
• Nelson EA, Bresee JS, Parashar UD, Widdowson MA, Glass RI; Asian Rotavirus Surveillance Network. Rotavirus epidemiology: the Asian Rotavirus Surveillance Network. Vaccine26(26), 3192–3196 (2008).
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al.; Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med.354(1), 11–22 (2006).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P et al.; Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med.354(1), 23–33 (2006).
   PubMed Web of Science ®Google Scholar
• Linhares AC, Velázquez FR, Pérez-Schael I et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled Phase III study. Lancet371(9619), 1181–1189 (2008).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind, placebo-controlled study. Lancet370(9601), 1757–1763 (2007).
   PubMed Web of Science ®Google Scholar
• Block SL, Vesikari T, Goveia MG et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics119(1), 11–18 (2007).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Itzler R, Karvonen A et al. RotaTeq®, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine28(2), 345–351 (2009).
   PubMed Web of Science ®Google Scholar
• Tate JE, Panozzo CA, Payne DC et al. Decline and change in seasonality of U.S. rotavirus activity after the introduction of rotavirus vaccine. Pediatrics124(2), 465–471 (2009).
   PubMed Web of Science ®Google Scholar
• Panozzo C, Tate J, Payne D et al. Impact of the new rotavirus vaccination program on severe rotavirus disease in US children. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 390).
   Google Scholar
• CDC. Reduction in rotavirus after vaccine introduction, United States, 2000–2009. MMWR Morb. Mortal. Wkly Rep.58(41), 1146–1149 (2009).
   PubMedGoogle Scholar
• WHO. Global Advisory Committee on Vaccine Safety, report of meeting held 17–18 June 2009. Wkly Epidemiol. Rec.84(32), 325–332 (2009).
   Google Scholar
• Belongia EA, Irving SA, Shui IM et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr. Infect. Dis. J.29(1), 1–5. (2010).
   PubMed Web of Science ®Google Scholar
• WHO. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 – conclusions and recommendations. Wkly Epidemiol. Rec.84(23), 220–236 (2009).
   PubMedGoogle Scholar
• de Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert. Rev. Vaccines7(3), 345–353 (2008).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Itzler R, Matson DO et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated healthcare utilization across 3 regions (11 countries). Int. J. Infect. Dis.11(Suppl. 2), 29–35 (2007).
   PubMed Web of Science ®Google Scholar
• Patel M, Pedreira C, De Oliveira LH et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA301(21), 2243–2251 (2009).
   PubMed Web of Science ®Google Scholar
• Patel M, Pedreira C, De Oliveira LH et al. Effectiveness of a pentavalent rotavirus vaccine in Nicaragua. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 385).
   Google Scholar
• Sanchez K, González F. Rotavirus vaccination in Nicaragua and infant mortality by acute diarrhea in 2007. Presented at: The 12th Annual Conference on Vaccine Research. Baltimore, MD, USA, 27–29 April 2009.
   Google Scholar
• Orozco M, Vasquez J, Pedreira C et al. Uptake of rotavirus vaccine and national trends of acute gastroenteritis among children in Nicaragua. J. Infect. Dis.200(Suppl. 1), 125–130 (2009).
   PubMedGoogle Scholar
• El Khoury A, Mast TC, Ciarlet ML et al. Projecting the efficacy of Rotateq® against rotavirus related hospitalizations in Brazil. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 614).
   Google Scholar
• Quintanar-Solares M, Richardson V, Hernandez-Pichardo J et al. Reduction in childhood diarrhea deaths after rotavirus vaccine introduction in Mexico. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 388).
   Google Scholar
• Bokser V, Califano G, Coarasa A et al. Incidence of diarrhea in children vaccinated with monovalent oral rotavirus vaccine in the Elizelda Children’s Hospital, Buenos Aires city, Argentina. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 523).
   Google Scholar
• Phua KB, Lim FS, Lau YL et al. Human rotavirus vaccine RIX4414 (Rotarix™) is highly efficacious in infants from Asia during the first two years of life. Presented at: 13th International Congress on Infectious Diseases. Kuala Lumpur, Malaysia, 19–22 June 2008 (Abstract 19.024).
   Google Scholar
• Phua KB, Lim FS, Lau YL et al. Human rotavirus vaccine RIX4414 is highly efficacious in Asian infants during the third year of life. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009 (Abstract 572).
   Google Scholar
• Cunliffe K, Kirsten M, Madhi S et al. Efficacy of human rotavirus vaccine RIX4414 in Africa during the first year of life. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009 (Abstract 449).
   Google Scholar
• Madhi S, Kirsten M, Bos P et al. Efficacy of the human rotavirus vaccine R1X4414 against rotavirus G2P[4]/G8P[4] strains in South African infants. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 670).
   Google Scholar
• Neuzil K, Madhi S, Cunliffe K et al. Immunogenicity of human rotavirus vaccine r1x4414 in South African and Malawian infants. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 539).
   Google Scholar
• O’Ryan M, Linhares AC. Update on Rotarix: an oral human rotavirus vaccine. Expert. Rev. Vaccines8(12), 1627–1641 (2009).
   PubMed Web of Science ®Google Scholar
• McIntyre P, Wood N. Pertussis in early infancy: disease burden and prevention strategies. Curr. Opin Infect. Dis.222(3), 215–223 (2009).
   Google Scholar
• Liese J. Key lessons from routine childhood pertussis immunisation. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 1078).
   Google Scholar
• Halperin SA. Recent experience with adolescent and adult pertussis boosters. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 1077).
   Google Scholar
• Ulloa-Gutierrez R. Pertussis vaccination in newborns. Expert Rev. Vaccines8(2), 153–157 (2009).
   PubMed Web of Science ®Google Scholar
• Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine25(14), 2634–2642 (2007).
   PubMed Web of Science ®Google Scholar
• Mertsola J, Booy R, Zepp F et al. The safety of repeated administration of reduced antigen content dTPa boosters. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 647).
   Google Scholar
• Mertsola J, Booy R, He Q et al. The immunogenicity of repeated administration of reduced antigen content dTPa booster vaccine in adults. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 633).
   Google Scholar
• Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Expert Rev. Vaccines7(9), 1367–1394 (2008).
   PubMed Web of Science ®Google Scholar
• Dinleyici EC, Yargic ZA. 27th Annual Meeting of the European Society for Pediatric Infectious Disease. Expert Rev. Vaccines8(9), 1143–1149 (2009).
   Google Scholar
• Dagan R. The role of vaccines in the prevention of pneumococcal pneumonia. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009.
   Google Scholar
• Brandileone MC, Brandao A, Almeida S et al.Streptococcus pneumoniae invasive disease in Latin American and Caribbean region: laboratorial surveillance network (SIREVA II, PAHO/WHO). Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 584).
   Google Scholar
• Brito MJ. Invasive pneumococcal disease (IPD) in children in Portugal prospective study (2006–2008). Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 712).
   Google Scholar
• Fenoll A, Aguilar L, Vicioso MD et al. Serotype distribution of Spanish Streptococcus pneumoniae isolates from pleural fluid (1997–2008). Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 217).
   Google Scholar
• Fenoll A, Gimenez MJ, Vicioso MD et al. Trends of the ten most prevalent pneumococal serotype among invasive isolates from children in the last 12 years in Spain. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 262).
   Google Scholar
• Fenoll A, Gimenez MJ, Vicioso MD et al. Trends of prevalent pneumococal serotypes among adult invasive isolates pre- and post-licensure of 7-PCV for children in Spain. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 260).
   Google Scholar
• Garcia Gabarrot G, Felix V, Camou T. Tempoarl trends of pediatric invasive pneumococcal disease serotypes. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 852).
   Google Scholar
• Levy C, Varon E, Bingen E et al. Effect of 7-valent pneumococal conjugate vaccine (PCV) on pneumococcal meningitis in French children. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 298).
   Google Scholar
• Cohen R, Levy C, Bonnet E et al. Does nasopharyngeal 7-valent conjugate vaccine continue to change nasopharyngeal carriage of S. pneumoniae? Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 296).
   Google Scholar
• Syriopoulou V, Syrogiannopoulos GA, Koutouzis E et al. Pediatric pneumococcal serotype epidemiology after the introdcution of heptavalent conjugated pneumococcal vaccine in Greece: an interim analysis. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 261).
   Google Scholar
• Gutierrez S, Boix AI, Gotelo G, Silva L. Bacterial pneumonia. Hospital admission to the Sindicato Medico Urugay (CASMU) one year before and after introduction of 7-valent pneumococcal vaccine. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 455).
   Google Scholar
• Cedres A, Sobrero H, Giachetto G et al. 7-valent pneumococcal conjugate vaccine mass vaccination. Bacterial pneumonia admissions in children before and during the year of intervention. Uruguay. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 793).
   Google Scholar
• Delfino M, Mas M, Barrios P et al. 7 valent pneumococal conjugate vaccine mass vaccination. Empyema in children before and during the year of intervention. Uruguay. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 517).
   Google Scholar
• Dinleyici EC, Yargic ZA. Pneumococcal conjugate vaccine: PHiD-CV. Expert Rev. Anti Infect. Ther.7(9), 1063–1074 (2009).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr. Infect. Dis. J.28(4 Suppl.), S66–S76 (2009).
   PubMed Web of Science ®Google Scholar
• Knuf M, Szenborn L, Moro M et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr. Infect. Dis. J.28(4 Suppl.), S97–S108 (2009).
   PubMed Web of Science ®Google Scholar
• Wysocki J, Tejedor JC, Grunert D et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr. Infect. Dis. J.28(4 Suppl.), S77–S88 (2009).
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet367(9512), 740–748 (2006).
   PubMed Web of Science ®Google Scholar
• Bakaletz LO. Chinchilla as a robust, reproducible, and polymicrobial model of otitis media and its prevention. Expert Rev. Vaccines8(8), 1063–1082 (2009).
   PubMed Web of Science ®Google Scholar
• Prymula R, Hanovcova I, Splino M et al. The 10-valent pneumococcal vaccine conjugated to protein D (PHiD-CV) reduces nasopharyngeal carriage of Streptococcus pneumoniae (SP) vaccine serotypes in Czech children. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 1113).
   Google Scholar
• Omenaca F, Constantopoulos A, Merino JM et al. Vaccination of preterm infants with 10-valent pneumococcal non-typeable Haemophilus influenza protein D conjugate vaccine (PHiD-CV). Pediatr. Infect. Dis. J.28(6), E190 (2009).
   Google Scholar
• Omenaca F, Kafetzis D, Merino JM et al. Booster vaccination of preterm-born children with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV): immunogenicity and safety. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 551).
   Google Scholar
• Bakir M, Turel O, Chen YC. Cost–effectiveness of the new 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Turkey. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 1124).
   Google Scholar
• Villasenor-Sierra A, de la Torrez-Gonzalez C, Martinez-Aguilar G et al. Cost–effectiveness of the new 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexico. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 951).
   Google Scholar
• Dinleyici EC, Yargic ZA. Current knowledge regarding the 13-valent pneumococcal conjugate vaccine. Expert Rev. Vaccines8(8), 978–986 (2009).
   Google Scholar
• Simoes E, Lucero M, Nohynek H et al. Safety of an 11-valent pneumococcal conjugate vaccine (11-PCV) in children aged 1 ½ to 24 months, in Bohol, Phillipines. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 654).
   Google Scholar
• Simoes E, Nohynek H, Lucero M et al. Efficacy of an 11 valent pneumococcal (11PCV) vaccine against severe and non-severe viral lower respiratory infection (LRI), in Bohol, Phillipines. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 291).
   Google Scholar
• Quian J, Rüttimann R, Romero C et al. Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997–2005. Arch. Dis. Child.93, 845–850 (2008).
   PubMed Web of Science ®Google Scholar
• Quian J, Ruttimann R, Protasio A, Dall’Orso P, Romero C, Mas M. Reduction in hospitalizations and ambulatory visits eight years after introduction of universal mass vaccination against varicella in Urguayan experience. Pediatr. Infect. Dis. J.28(6), e193 (2009).
   Google Scholar
• Quian J. Varicella vaccination: the Uruguay experience. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 1060).
   Google Scholar
• Lopez AS, Guris D, Zimmerman L et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics117, e1070–e1077 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. ACIP provisional recommendations for prevention of varicella. CDC, GA, USA (2006).
   Google Scholar
• Bonanni P, Breuer J, Gershon A et al. Varicella vaccination in Europe – taking the practical approach. BMC Med.7, 26 (2009).
   PubMed Web of Science ®Google Scholar
• Prymula R, Kulcsar A, Nemec V et al. Immunogenicity of two doses of varicella vaccine in the second year of life determined using two serological assays. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 676).
   Google Scholar
• Levin M, Wright V, Davila S et al. Pathophysiology and genetic of meningococcal disease. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 669).
   Google Scholar
• Safadi M. Global epidemiology of group C meningococcal disease: where are we now? Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 1067).
   Google Scholar
• De Lemos AP, Gorla MC, Brandileone MC et al. Invasive meningococcal disease in Latin America and Caribbean region: the experience of SIREVA II (PAHO/WHO) network. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 268).
   Google Scholar
• Corso A, Gagetti P, Sorhouet Pereira C et al. Nation surveillance on antimicrobial resistance and serogroups of Neisseria meningitidis (NME) isolates causing invasive disease in Argentina: 1998–2008. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 312).
   Google Scholar
• Safadi M. Advances towards comprehensive meningococcal disease protection: worldwide experience. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 1051).
   Google Scholar
• Pollard A. Vaccines against meningococcal B infections. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 1055).
   Google Scholar
• Knuf M, Kieninger-Baum D, Habermehl P et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine28(3), 744–753 (2010).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Lindbland N et al. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (MenACWY–TT) vaccine in toddlers and children after one year. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 582).
   Google Scholar
• Borja-Tabora C, Montalban C, Memish Z et al. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (MenACWY–TT) vaccine in 11–17 years old. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 568).
   Google Scholar
• Ward J. Development of a meningococcal serogroup B (MenB) vaccine for global use. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases – WSPID. Buenos Aires, Argentina, 18–22 November 2009 (Abstract 650).
   Google Scholar